Immunological Markers in Adult Patients With Immune Thrombocytopenic Purpura

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-04-12

Study Completion Date

2015-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to determine histological immunological parameters, sought on splenectomy pieces that may explain the failure or success of splenectomy in patients with ITP who had a splenectomy to treat their ITP(Immune thrombocytopenic purpura).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Initial Hemato-immunological Profile on the Evolution of Immunological Thrombopenic Purpura.

NCT04070599

Immune Thrombocytopenic Purpura Autoimmune Thrombocytopenia Thrombopenia

COMPLETED PHASE3

Retrospective & Prospective Observational Study of Patients With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

NCT00454857

Idiopathic Thrombocytopenic Purpura Thrombocytopenia Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) +1 more

COMPLETED

An Epidemiological Study of Subjects With Immune Thrombocytopenic Purpura to Evaluate the Relationship Between Platelet Counts, Endogenous Thrombopoietin Levels, Endogenous Anti-Thrombopoietin Antibodies, and Selected Autoimmune Markers

NCT00005570

Purpura, Thrombocytopenic, Idiopathic Immune Thrombocytopenic Purpura

COMPLETED

Research of Predictive Factors to Immune Thrombopenic Purpura

NCT01648556

Purpura Thrombopenic

UNKNOWN NA

Diagnostic of Chronic Thrombocytopenia

NCT04071496

Congenital Thrombocytopenia Chronic Idiopathic Thrombocytopenic Purpura

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Immune thrombocytopenic purpura (ITP) is a rare autoimmune thrombocytopenia whose incidence is 2 to 5 cases / 100,000 inhabitants / year. The potentially serious haemorrhagic risk is the major issue of management. A recent international consensus conference classifies PTI according to the duration of thrombocytopenia: acute ITP (\<3 months), persistent ITP (3-12 months) and chronic ITP (\> 12 months) (Rodeghiero 2009). In the acute or persistent phase, polyvalent immunoglobulins (IVIG) and / or corticosteroids are proposed. In the chronic phase, splenectomy is a possible cure for 70% of patients. No predictor of treatment response is known.

The pathophysiology of ITP is multifactorial: platelet phagocytosis, mediated by autoantibody, macrophages of the reticuloendothelial system, and destruction in the spleen, genetic background and / or environmental factor favoring the role of certain lymphocyte subpopulations, cytotoxic or regulatory T, via their cytokine environment, abnormalities of thrombopoiesis.

At present, no predictive factor of splenectomy success has been identified. The aim of this study is to determine histological immunological parameters, sought on splenectomy pieces that may explain the failure or success of splenectomy in patients with ITP who had a splenectomy to treat their ITP.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Immune Thrombocytopenic Purpura Splenectomy; Status

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ITP group

On frozen spleens of already splenectomized adult ITP patients.

Immunolabeling

Intervention Type PROCEDURE

Immunolabeling of abnormalities observed by the cell study in flow cytometry.

Control group

On frozen control spleens from patients who had a splenectomy at the Bordeaux University Hospital following a road accident.

Immunolabeling

Intervention Type PROCEDURE

Immunolabeling of abnormalities observed by the cell study in flow cytometry.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Immunolabeling

Immunolabeling of abnormalities observed by the cell study in flow cytometry.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The analyzed spleens belong to the collection of biological samples declared to the ministry by the Laboratory of Pathology of Haut-Lévêque Hospital (Dr Parrens).